ZIOPHARM Oncology, Inc. (ZIOP) escalated 3.15% and closed its last trading session at $4.26. Its opening price on the last trading day was $4.13. The company’s market cap is $604.75 Million. The company has 141.96 Million shares outstanding and 139.65 Million shares were floated in market. The short ratio in the company’s stock is documented at 19.05 and the short float is around of 24.84%. ZIOPHARM Oncology, Inc. has been given an analysts’ mean target of 12.5.
The highest price ZIOP stock touched in the last 12 month was $7.88 and the lowest price it hit in the same period was $3.77. Stock’s distance from 52 week High is -45.94% and the distance from 52 week Low is 13%.
Share Volume Analysis
A total of 1.84 Billion shares exchanged at hands and its average trading volume is standing at 1.82 Million shares. The relative volume of the stock is 1.01.
ZIOPHARM Oncology, Inc. (ZIOP) performance during the last one year degraded -21.26 percent, while its year to date (YTD) performance showed a positive trend of 2.9 percent. The stock fell -28.52 percent over the past six months. The stock’s quarterly performance indicates a negative momentum of -25.52 percent, whereas its last one month trend is optimistic with 1.43 percent. Its weekly performance showed downward trend of -2.74 percent.
Profit Margins Analysis
Profitability analysis helps a great deal in making investment decision. Net profit margin of the company was recorded at 0 percent, operating profit margin was 0 percent, while gross profit margin stands at 0 percent.
Key Ratios Review
Liquidity ratios help investors to determine a company’s ability to pay off its debts. For the most recent quarter, quick ratio was 6.3, current ratio was 6.3, LT Debt/Equity ratio was 0 and Total Debt/Equity ratio stands at 0, while Payout ratio is 0.
Return on Assets, Investment and Equity
ZIOPHARM Oncology, Inc. (ZIOP) has a Return on Assets of -62.8 percent, Return on Investment of 213.9 percent and a Return on Equity of 88.2 percent.
Simple Moving Average
Moving averages are used as a strong indicator for technical stock analysis and it helps investors in figuring out where the stock has been and also helps in determining where it may be possibly heading. Now we look at the Moving Averages, the 200-day is -25.45%, the 50-day is -2.62% and the 20-day is 0.5%.
EPS Growth Analysis
The company’s diluted EPS for trailing twelve months was -0.52.
EPS Estimate for the next year is -0.58.
EPS Estimate for the next Quarter is -0.13.
EPS Growth this year is -38.1 percent.
Earnings and Sales Growth
EPS growth for the next 5 years is 0 percent.
Annual EPS growth Past 5 years is -6.5 percent.
Annual Sales Growth in the past 5 years was 59.4 percent.
Quarterly Revenue Growth on year-over-year basis stands at 0 percent.
Quarterly Earnings Growth on year-over-year basis stands at -13.1 percent.
Investment Valuation Ratios
The company P/E (price to earnings) ratio is 0 and Forward P/E ratio is 0. The company P/S (price to Sales) ratio is 94.49, P/B (price to Book) ratio is 0, while its P/C (price to Cash) ratio stands at 7.17.
If we look at the Volatility of ZIOPHARM Oncology, Inc. (ZIOP), Week Volatility is 6.33%, whereas Month Volatility is at 6.03%.
ZIOPHARM Oncology, Inc. (ZIOP)’s RSI (Relative strength index) is at 50.3, its ATR (Average True Range) value is 0.27, while its Beta factor was calculated at 1.54.
Earnings Release Date
The company is estimated to report earnings on Feb 05 AMC.
ZIOPHARM Oncology, Inc. (ZIOP) has an Analysts’ Mean Recommendation of 2.5.
Insider Ownership and Transactions
ZIOPHARM Oncology, Inc.’s insider ownership stands at 1.4 percent, while its insider transaction is 0.54 percent.
Institutional Ownership and Transactions
Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments. ZIOPHARM Oncology, Inc.’s institutional ownership is 50.2%, while its institutional transactions stand at 0.05%.